@article{TLCR34597,
author = {Maja Šutić and Antje Motzek and Gordana Bubanović and Matthias Linke and Ivan Sabol and Oliver Vugrek and Petar Ozretić and Luka Brčić and Sven Seiwerth and Željko Debeljak and Antonija Jakovčević and Zoran Janevski and Dinko Stančić-Rokotov and Andrea Vukić-Dugac and Marko Jakopović and Miroslav Samaržija and Ulrich Zechner and Jelena Knežević},
title = {Promoter methylation status of ASC/TMS1/PYCARD is associated with decreased overall survival and TNM status in patients with early stage non-small cell lung cancer (NSCLC)},
journal = {Translational Lung Cancer Research},
volume = {8},
number = {6},
year = {2020},
keywords = {},
abstract = {Background: Lung cancer is the leading cause of cancer-related death worldwide, with 5-year overall survival less than 15%. Therefore, it is essential to find biomarkers for early detection and prognosis. Aberrant DNA methylation is a common feature of human cancers and its utility is already recognized in cancer management. The aim of this study was to explore the diagnostic and prognostic value of the promoter methylation status of the ASC/TMS1/PYCARD and MyD88 genes, key adaptor molecules in the activation of the innate immune response and apoptosis pathways.
Methods: A total of 50 non-small cell lung cancer (NSCLC) patients were enrolled in the study. Meth- ylation of bisulphite converted DNA was quantified by pyrosequencing in fresh frozen malignant tissues and adjacent non-malignant tissues. Associations between methylation and lung function, tumor grade and overall survival were evaluated using receiver-operating characteristics (ROC) analysis and statistical tests of hypothesis.
Results: Methylation level of tested genes is generally low but significantly decreased in tumor tissues (ASC/ TMS1/PYCARD, P},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/34597}
}